Investor Conference Call and Webcast at NLA 2019 Scientific Sessions

  • Date:
  • Time:
  • Location: Miami

The Medicines Company will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company’s management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study. The data will be presented during the late-breaking clinical trial session earlier the same day at the National Lipid Association (NLA) 2019 Scientific Sessions in Miami.

Inclisiran, the first cholesterol-lowering therapy in the small interfering RNA (siRNA) class, is the only medicine in late-stage clinical development with the potential to deliver potent, durable and consistent lowering of LDL cholesterol through twice-a-year dosing.

ORION-3 is an open-label Phase 2, extension study (of ORION-1) to assess the efficacy, safety and tolerability of long-term dosing of inclisiran. The study also evaluates safety and efficacy of switching patients treated with evolocumab to inclisiran. Follow up for this latter group is still ongoing and will be presented at a later date.

Conference Call

The conference call may be accessed as follows:

U.S./Canada: (877) 407-0312

International: (201) 389-0899

Conference ID: 13690839

A taped replay of the conference call will be available for approximately one month. The replay may be accessed as follows:

U.S./Canada: (877) 660-6853

International: (201) 612-7415

Conference ID: 13690839

Webcast

A live audio webcast of the conference call and slides is available here.

An on-demand replay of the webcast will be available after the call concludes at the same location.

Callers accessing the conference call by phone, who wish to view the slide deck, can do so here.

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com